Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Oct 2012

Erčulj Nina, Kovač Viljem, Hmeljak Julija, Franko Alenka, Dodič-Fikfak Metoda, Dolžan Vita

Abstract excerpt

INTRODUCTION: Genetic polymorphisms that affect DNA repair capacity can modulate the efficacy and toxicity of cytotoxic agents. Therefore, the aim of our study was to evaluate the influence of genetic variability in DNA repair genes on treatment outcome in patients with malignant mesothelioma (MM) treated with gemcitabine-platinum combination chemotherapy. METHODS: In total, 109 patients with MM were genotyped...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Deoxycytidine
Share to Gemcitabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mesothelioma

Share to Peritoneal Neoplasms

Share to Platinum

Share to Pleural Effusion, Malignant

Share to Rad51 Recombinase

Share to X-ray Repair Cross Complementing Protein 1

Source

Identifiers

PMID: 22982660
DOI: 10.1097/JTO.0b013e3182653d31

Genes

XRCC1
NBN
XRCC3
RAD51

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy.PMID 22982660Read ↗

The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma.Semantic proximity Read ↗

The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesotheliomaSemantic proximity Read ↗

Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.Semantic proximity Read ↗

Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy.Semantic proximity Read ↗

Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.Semantic proximity Read ↗

Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis.Semantic proximity Read ↗

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.Semantic proximity Read ↗

DNA repair systems in malignant mesothelioma.Semantic proximity Read ↗

Polymorphisms in translesion polymerase genes influence treatment outcome in malignant mesothelioma.Semantic proximity Read ↗

Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy.Semantic proximity Read ↗

Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.Semantic proximity Read ↗

Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.